- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John Theurer Cancer Center, Hackensack University Medical Center | Strategic Alliance Partners
ABOUT HACKENSACK UNIVERSITY MEDICAL CENTER
Hackensack University Medical Center, a 803-bed nonprofit teaching and research hospital, was Bergen County’s first hospital founded in 1888. It was also the first hospital in New Jersey and second in the nation to become a Magnet®-recognized hospital for nursing excellence, receiving its sixth consecutive designation from the American Nurses Credentialing Center. The academic flagship of the Hackensack Meridian Health network, Hackensack University Medical Center is Nationally-Ranked by U.S. News & World Report 2022-2023 in four specialties, more than any other hospital in New Jersey. The hospital is home to the state's only nationally-ranked Urology and Neurology & Neurosurgery programs, as well as the best Cardiology & Heart Surgery program. It also offers patients nationally-ranked Orthopedic care and one of the state’s premier Cancer Centers (John Theurer Cancer Center at Hackensack University Medical Center). Hackensack University Medical Center also ranked as High-Performing in conditions such as Acute Kidney Failure, Heart Attack (AMI), Heart Failure, Pneumonia, chronic obstructive pulmonary disease (COPD), Diabetes and Stroke. As well as High Performing in procedures like Aortic Valve Surgery, Heart Bypass Surgery (CABG), Colon Cancer Surgery, Lung Cancer Surgery, Prostate Cancer Surgery, Hip Replacement and Knee Replacement. Named to Newsweek’s World’s Best Hospitals 2023 list, Hackensack University Medical Center is also the recipient of the 2023 Patient Safety Excellence Award™ by Healthgrades as well as an “A” Hospital Safety Grade from The Leapfrog Group. This award-winning care is provided on a campus that is home to facilities such as the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women’s and Children’s Pavilion, which houses the Donna A. Sanzari Women’s Hospital and the Joseph M. Sanzari Children’s Hospital, ranked #1 in the state and top 20 in the Mid-Atlantic Region in the U.S. News & World Report’s 2022-23 Best Children’s Hospital Report. Additionally, the children’s nephrology program ranks in the top 50 in the United States. Hackensack University Medical Center is also home to the Deirdre Imus Environmental Health Center and is listed on the Green Guide’s list of Top 10 Green Hospitals in the U.S. Our comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development. The hospital has embarked on the largest healthcare expansion project ever approved by the state: Construction of the Helena Theurer Pavilion, a 530,000-sq.-ft., nine-story building, which began in 2019. A $714.2 million endeavor, the pavilion is one the largest healthcare capital projects in New Jersey and will house 24 state-of-the-art operating rooms with intraoperative MRI capability, 50 ICU beds, and 175 medical/surgical beds including a 50 room Musculoskeletal Institute.
Latest from John Theurer Cancer Center, Hackensack University Medical Center
Dr. Goy on the Evolution of Treatment Selection in MCL
May 12, 2020
Video
Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.
PET Scans and Novel Therapies Propel Progress in Hodgkin Lymphoma
May 12, 2020
Article
Tatyana Feldman, MD, discusses the significance of PET-adapted strategies in Hodgkin lymphoma, novel therapies that have emerged in the pipeline, and where future research is headed.
Procedural Redesign of VATS in Lung Cancer Improves Quality of Care and Reduces Cost
May 12, 2020
Article
Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery.
Dr. Goy on Research Efforts With BTK Inhibitors in MCL
May 12, 2020
Video
Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.
Dr. Goy on Research Efforts With BTK Inhibitors in MCL
May 11, 2020
Video
Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.
Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL
May 10, 2020
Video
Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.
Dr. Goy on Comparing the Toxicity Profiles of BTK Inhibitors in MCL
May 08, 2020
Video
Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.
Dr. Feldman on the Utility of PET Scan in Hodgkin Lymphoma
April 23, 2020
Video
Tatyana Feldman, MD, discusses the utility of PET Scan in Hodgkin Lymphoma.
Dr. Goy on the Progression of MCL Treatment
April 08, 2020
Video
Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.
Goy Underscores Impact of BTK Inhibitors in Relapsed/Refractory MCL
April 07, 2020
Article
Andre Goy, MD, MS, discusses the utility of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.
Dr. Feldman on the Shortcomings of PET Scan in Hodgkin Lymphoma
March 26, 2020
Video
Tatyana Feldman, MD, discusses the shortcomings of PET scan in Hodgkin lymphoma.
Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous Carcinoma
March 13, 2020
Video
Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.
Dr. Hellmann on the Impact of Systemic Therapy on Surgery in Ovarian Cancer
March 10, 2020
Video
Mira Hellmann, MD, discusses the impact of surgery on patients with ovarian cancer.
John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma
March 04, 2020
Article
An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab improves recurrence-free survival compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.
Dr. Hellmann on Benefit of PARP Inhibitors in Patients With Ovarian Cancer
March 03, 2020
Video
Mira C. Hellmann, MD, discusses the benefit of PARP inhibitors in patients with ovarian cancer.
Dr. Goy on Combinations With Novel Agents in Relapsed/Refractory MCL
February 14, 2020
Video
Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.
Dr. Goy the Evolution of Treatment in Relapsed/Refractory MCL
February 11, 2020
Video
Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.
Dr. Goy on the Utility of Novel Agents in MCL
February 04, 2020
Video
Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).
Dr. Biran on Post-ASCT Consolidation in Multiple Myeloma
February 01, 2020
Video
Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.
Dr. Gutierrez on the Safety Profile of Pembrolizumab-Based Combos in NSCLC
January 31, 2020
Video
Martin E. Gutierrez, MD, director, co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the safety profile of pembrolizumab (Keytruda)-based combination strategies in non-small cell lung cancer (NSCLC).